(Q37883014)

24 August 2017

1 reference

title

Differing levels of testosterone and the prostate: a physiological interplay (English)

1 reference

24 August 2017

1 reference

1 reference

S Larry Goldenberg

1

1 reference

24 August 2017

Anthony Koupparis

series ordinal

2

1 reference

24 August 2017

Michael E Robinson

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

24 August 2017

published in

Nature Reviews Urology

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

365-377

1 reference

ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

METABOLISM OF THE ACCESSORY SEX ORGANS OF THE IMMATURE MALE RAT: CHANGES IN NUCLEIC ACID COMPOSITION AND UPTAKE OF THYMIDINE-3-H INDUCED BY CASTRATION AND METHANDROSTENOLONE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Differential Effect of 5α-Reductase Inhibition and Castration on Androgen-Regulated Gene Expression in Rat Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone and prostate cancer: an historical perspective on a modern myth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate cancer risk in testosterone-treated men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Absence of relationship between steroid hormone levels and prostate cancer tumor grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Circulating steroid hormones and the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Hormones and prostate cancer: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Characterization of androgen-regulated expression of CYP3A5 in human prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Oestrogens and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Diabetes mellitus and risk of prostate cancer (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Reduced risk of prostate cancer among patients with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Is the flare phenomenon clinically significant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate-specific antigen: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Intermittent androgen suppression for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Impotence therapy and cancer of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostatic complications of testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate cancer after exogenous testosterone treatment for impotence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate cancer in men using testosterone supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy in hypogonadal men and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy and the risk of prostate cancer: a perspective view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy and the risk of prostate cancer. Is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone for the aging male; current evidence and recommended practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone therapy and prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement therapy following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Androgen replacement in men undergoing treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Low serum testosterone and mortality in male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Low serum testosterone and mortality in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Low serum testosterone and increased mortality in men with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Adverse events associated with testosterone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Effect of duration of the period after castration on the response of the rat ventral prostate to androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The effects of testosterone, 5 -dihydrotestosterone and adenosine 3',5'-monophosphate on cell proliferation and differentiation in rat prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone therapy in men with untreated prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone dose-response relationships in healthy young men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Adenocarcinoma of prostate in 40-year-old body-builder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Association of specific symptoms and metabolic risks with serum testosterone in older men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.79

Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells

31 March 2020

1 reference

12 December 2020

A ten-year safety study of the oral androgen testosterone undecanoate.

1 reference

12 December 2020

Hormonal control of neoplastic growth

1 reference

12 December 2020

Endocrine-induced regression of cancers

1 reference

12 December 2020

Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Discussion of Dr. Huggins' paper: Control of cancers of man by endocrinological methods

1 reference

12 December 2020

Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk

1 reference

12 December 2020

Leptin is associated with increased prostate cancer risk: a nested case-referent study

1 reference

12 December 2020

Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement

1 reference

12 December 2020

Hormonal Effects on Cell Proliferation in Rat Prostate

1 reference

12 December 2020

High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study

1 reference

12 December 2020

The benefits and risks of testosterone replacement therapy: a review

1 reference

12 December 2020

Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men

1 reference

12 December 2020

The role of steroid hormones in prostate carcinogenesis

1 reference

12 December 2020

Prostatic cancer; further investigation of hormonal relationships

1 reference

12 December 2020

Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels

1 reference

12 December 2020

Androgen replacement therapy after prostate cancer treatment

1 reference

12 December 2020

Effects of testosterone supplementation in the aging male

1 reference

12 December 2020

Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

1 reference

12 December 2020

The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer

1 reference

12 December 2020

Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma

1 reference

12 December 2020

Effects of testosterone replacement in hypogonadal men.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.79

1 reference

24 August 2017

1 reference